Analysis of molecular subtypes and prognostic signature of senescence-associated secretory phenotype in pancreatic cancer
Kuang Y., Jia M., Zhu Y., Xiang Z.
Prospective Study, published in PeerJ (2026) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- PeerJ (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41522514
- PMCID
- PMC12786131
- DOI
- 10.7717/peerj.20476
Abstract (original English)
Background Pancreatic cancer (PC) exhibits an extremely poor prognosis due to its high heterogeneity. The senescence-associated secretory phenotype (SASP), a distinct secretory profile displayed by senescent cells, has been increasingly studied. However, the role of SASP in PC prognosis and treatment remains unclear. Methods Transcriptomic sequencing data from PC patients were analyzed using consensus clustering based on SASP genes. A prognostic signature was subsequently constructed via Least Absolute Shrinkage and Selection Operator (LASSO) regression using survival-related SASP genes. Pathway enrichment analysis for distinct subgroups was performed using Gene Set Variation Analysis (GSVA). Comprehensive analyses of mutational landscapes and tumor immune microenvironments were conducted across risk-stratified PC samples. Results Consensus clustering based on SASP genes identified two SASP-associated clusters (SASPclusters), with cluster B demonstrating significantly worse prognosis than cluster A. Thirty-three SASP genes showed significant associations with PC prognosis, and a 7-gene SASP-based prognostic signature was established. High-risk patients exhibited significantly higher mutation rates. Distinct immune cell infiltration patterns, immune functions, checkpoint expression levels, and chemosensitivity profiles were observed between risk groups. Besides, we found that AN
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.